Guide for Pharmaceutical Manufacturing Industry Research & Development Medical Pharmacy Students FDA updates Guidelines
Custom Search
Showing posts with label Ebola Virus Vaccine. Show all posts
Showing posts with label Ebola Virus Vaccine. Show all posts

Sunday, October 18, 2020

USFDA approves first drug Inmazeb to treat Ebola Virus Infection

US FDA approved first drug to treat Ebola Virus Infection (zaire ebolavirus) . So far there was no drug treatment available for Ebola virus infection, and Ebola virus infection is more deadly than Corona Virus ( SARS-COV-2 ) 

The patient infected with the Ebola Virus would start bleeding from the skin, and the the virus too is very infectious spreads by direct contact with infected persons blood, or serum, or contaminated cloths bedsheets, ect.

The drug Inmazeb is a fixed dose combination of three monoclonal antibodies

1) Atoltivimab

2) Maftivimab

3) Odesivimab

last letter in "mab" represents "monoclonal antibodies

These three antibodies are specific to Ebola viral glycoprotein, which is responsible for process of infection in to our cells.

The drug Inmazeb is assigned as Orphan Drug Designation.

Last year in Dec 2019 US FDA has approved vaccine for Ebola Virus Infection (zaire ebolavirus), the vaccine is a recombinant live Recombinant vesicular stomatitis virus. The live recombinant virus vaccine when injected in to human produces glycoproteins of Ebola Virus thus triggers immunity against  Ebola Virus.

Ebola Virus


 You may also like : Ebola Vector Vaccine Research 

                                 Ebola Paper Strip Test

Monday, September 1, 2014

Vector vaccine against Ebola under way

Vaccine for Ebola Virus:

Vaccine against Ebola virus is under development, Vaccine Research Center in united states is in the process of developing a vaccine with collaboration of Okairos ( GSK ) this vaccine is an investigational vaccine it is a vector vaccine.Vector is a suitable microorganism, like bacteria or virus (bacteriophages), which is used to deliver genes which after insertion into human body start producing proteins of Ebola virus which in turn act as antigens, human body start identifying and put it into memory in immunity imparting cells, and develop a immune response against this antigen that can protect human body upon actual encounter with Ebola virus.

Hurdles in developing vaccine and drug:
 
There is no drug antigens for treating infection of Ebola virus, if at all all are in investigational stages, neither there is any vaccine, there are many hurdles in developing drug and vaccine. As virus has its own mechanism to protect itself from immune response, antibodies developed against Ebola virus in human body after infection are not able to fight against Ebola virus, they are ineffective.

Systematic analysis of this have resulted in finding that RNA of Ebola virus are protected with a cap like proteins which hinder the approach of antibody to and protect Ebola virus RNA. This protein is known as VP 35. In-depth study of protein VP 35 will give a path to develop a effective drug or a vaccine for treatment of Ebola Virus infection. Researches from The Scripps Research Institute and Iowa State University have studied crystal graphic structure of VP 35 protein bound to Ebola RNA.

Pharmaceutical Educational Website Autored by B V WAGHMARE

Pharmaceutical Educational Website Autored by B V WAGHMARE

Like This Website on Facebook and Stay Connected Share This Article with your Friends




Latest Pharma Update

USFDA approves first drug Inmazeb to treat Ebola Virus Infection

US FDA approved first drug to treat Ebola Virus Infection (zaire ebolavirus) . So far there was no drug treatment available for Ebola virus ...

You May Also Like

If you are looking for latest Pharmaceutical Manufacturing Guidelines of USFDA, UKMHRA, TGA WHO GMP then this website is one of most popular source.
Subscribe to this website by providing your email


Enter your email address get latest Pharma Guideline and technology update by email whenever this website is updated